WEBULL

Medtronic (MDT) Valuation Check After Analyst Upgrade And New Hugo And Symplicity Spyral Milestones

Simply Wall St · 3d ago

Medtronic (MDT) is back on investor radar after William Blair upgraded the stock to Outperform, highlighting fresh product catalysts related to its Hugo robotic surgery platform and Symplicity Spyral renal denervation system.

See our latest analysis for Medtronic.

That upgrade comes on the back of a 1-year total shareholder return of 29.55% and a 3-year total shareholder return of 40.22%. The share price, now at $100.31, has seen momentum pick up again recently after some shorter term softness, which hints that investors are reassessing growth potential and risks around Medtronic’s newer platforms.

If this kind of healthcare tech story interests you, it could be a moment to broaden your watchlist with healthcare stocks as potential long term ideas.

So with Medtronic trading at $100.31, a modest 3.8% intrinsic discount and about 10.6% below average analyst targets, you have to ask: is this still a mispriced opportunity, or is fresh growth already baked in?

Most Popular Narrative Narrative: 9.6% Undervalued

With Medtronic closing at $100.31 and the most followed narrative pointing to fair value around $110.97, the gap comes down to how confidently you see its product pipeline translating into earnings.

Medtronic's investments and breakthroughs in digital health technologies, robotics (Hugo), next-generation sensors, and AI-enabled ecosystems (e.g., spine AiBLE, advanced neuromodulation) align with industry-wide digital transformation and minimally invasive trends. These platforms are set to expand procedure volumes and capture market share, supporting future top-line growth and higher-margin revenue streams.

Read the complete narrative.

Curious what sits behind that value gap? The narrative leans on steady revenue uplift, firmer margins, and a future earnings multiple usually reserved for higher growth peers.

Result: Fair Value of $110.97 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this hinges on Medtronic turning heavy R&D spending into traction for platforms like Hugo, and managing any bumps around the planned Diabetes spin off.

Find out about the key risks to this Medtronic narrative.

Build Your Own Medtronic Narrative

If you see the numbers differently or prefer to weigh the assumptions yourself, you can build a custom view in minutes with Do it your way.

A great starting point for your Medtronic research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.

Looking for more investment ideas?

If Medtronic is on your radar, it is worth widening your search so you do not miss other opportunities that might fit your style and goals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.